Induction of EBV latent membrane protein-2A (LMP2A)-specific T cells and construction of individualized TCR-engineered T cells for EBV-associated malignancies

BACKGROUND: Latent membrane protein-2A (LMP2A)-specific TCR-engineered T cells could be a promising treatment approach to Epstein–Barr virus-associated malignancies. However, previous studies mainly reported LMP2A-reactive TCRs only focusing on specific HLA subtypes and corresponding epitopes, and t...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Chaoting, Tan, Qin, Li, Shance, Shen, Luyan, Zhang, Jingtao, Liu, Ying, Yang, Wenjun, Lu, Zheming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252876/
https://www.ncbi.nlm.nih.gov/pubmed/34210819
http://dx.doi.org/10.1136/jitc-2021-002516

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8252876/
https://www.ncbi.nlm.nih.gov/pubmed/34210819
http://dx.doi.org/10.1136/jitc-2021-002516

Ejemplares similares